Table 2.
MicroRNAs differentially expressed in malignant to matched non-malignant tissue samples of clear cell renal cell carcinoma (microarray results)
| MicroRNA | Fold changes† | P values | |
|---|---|---|---|
| Over-expressed | |||
| 1‡ | hsa-miR-122a | 41.4 | <0.0001 |
| 2‡ | hsa-miR-18a* | 6.8 | 0.0023 |
| 3‡ | hsa-miR-452* | 5.1 | 0.0001 |
| 4‡ | hsa-miR-224 | 4.4 | <0.0001 |
| 5‡ | hsa-miR-210 | 4.3 | 0.02479 |
| 6‡ | hsa-miR-34b | 3.5 | <0.0001 |
| 7‡ | hsa-miR-155 | 3.2 | 0.01047 |
| 8 | hsa-miR-34a | 2.9 | <0.0001 |
| 9 | hsa-miR-130b | 2.8 | <0.0001 |
| 10 | hsa-miR-21 | 2.5 | 0.0009 |
| 11 | hsa-miR-142–5p | 2.2 | 0.0171 |
| 12 | hsa-miR-193a | 2.2 | <0.0001 |
| 13 | hsa-miR-18a | 2.0 | <0.0001 |
| Under-expressed | |||
| 1‡ | hsa-miR-184 | −12.1 | 0.0004 |
| 2‡ | hsa-miR-514 | −9.5 | 0.0366 |
| 3‡ | hsa-miR-200c | −8.8 | 0.0075 |
| 4‡ | hsa-miR-510 | −8.1 | 0.0012 |
| 5‡ | hsa-miR-141 | −7.3 | 0.0262 |
| 6‡ | hsa-miR-138 | −5.2 | 0.0078 |
| 7‡ | hsa-miR-429 | −3.4 | <0.0001 |
| 8‡ | hsa-miR-200b | −3.1 | <0.0001 |
| 9‡ | hsa-miR-363 | −3.0 | <0.0001 |
| 10 | hsa-miR-532 | −2.7 | <0.0001 |
| 11 | hsa-miR-660 | −2.7 | <0.0001 |
| 12 | hsa-miR-362 | −2.7 | <0.0001 |
| 13 | hsa-miR-200a | −2.6 | <0.0001 |
| 14 | hsa-miR-10a | −2.5 | <0.0001 |
| 15 | hsa-miR-502 | −2.3 | 0.0005 |
| 16 | hsa-miR-204 | −2.3 | 0.0065 |
| 17 | hsa-miR-30a-3p | −2.2 | <0.0001 |
| 18 | hsa-miR-500 | −2.1 | <0.0001 |
| 19 | hsa-miR-30c | −2.1 | <0.0001 |
| 20 | hsa-miR-30a-5p | −2.0 | <0.0001 |
Abbreviation: hsa-miR, Homo sapiens microRNA
†
Mean fold changes of redundant microRNA sequences from 12 tissue pairs (paired t-test).
MicroRNAs (‡) showed at least three-fold changed expressions between malignant and the non-malignant samples by microarray analysis. MicroRNAs in italics showed Ct values >35 in RT-PCR of the pooled samples from set 1 and were excluded from further analyses (see text); microRNAs in bold letters were studied with RT-PCR in the sets 1 and 2.